<p><span style="color: #ee2323;"><b><span data-ke-size="size18">무슨 말인지 이해가 되지 않으시지요? 임상실험에 관한 정보 2개를 더 합쳐서 설명을 올리겠습니다.</span></b></span></p><p> </p><p><b><span data-ke-size="size18">Selected active disease-modifying projects in Parkinson's disease (Ph2 and 3)</span></b></p><div class="table-wrap"><table data-ke-type="table" data-ke-align="alignLeft" style="width: 100%;" border="1"><tbody><tr><td><b>Project</b></td><td><b>Description</b></td><td><b>Company</b></td><td><b>Trial, primary completion</b></td></tr><tr><td>Bydureon<br>(exenatide)</td><td>GLP-1 receptor agonist</td><td>Astrazeneca</td><td>Ph3 <a href="https://clinicaltrials.gov/ct2/show/NCT04232969" target="_blank" class="ke-link">Exenatide-PD3</a>, Jun 2023, sponsored by UCL</td></tr><tr><td>PRX002<br>(prasinezumab)</td><td>Anti-α-synuclein MAb</td><td>Roche/Prothena</td><td>Ph2b due to start Q2 2021 (ph2 <a href="https://clinicaltrials.gov/ct2/show/NCT03100149" target="_blank" class="ke-link">Pasadena</a> failed) </td></tr><tr><td>AAV-GAD</td><td>AAV GAD gene therapy</td><td>Meiragtx</td><td>Completed ph1 and <a href="https://clinicaltrials.gov/ct2/show/NCT00643890" target="_blank" class="ke-link">ph2</a>, IND expected H1 to start new trial</td></tr><tr><td>ANVS401<br>(phenserine)</td><td>Amyloid precursor protein, alpha-synuclein & tau inhibitor</td><td>Annovis Bio/Horizon Therapeutics</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04524351" target="_blank" class="ke-link">Ph2</a>, initial data due early 2021, dose-response data due late summer</td></tr><tr><td>AKST4290<br>(lazucirnon)</td><td>C-C chemokine receptor type 3 antagonist</td><td>Alkahest</td><td>Ph2 <a href="https://clinicaltrials.gov/ct2/show/NCT04369430" target="_blank" class="ke-link">Teal</a>, Mar 2021</td></tr><tr><td>CNM-Au8</td><td>Gold nanoparticles</td><td>Clene Nanomedicine</td><td>Ph2 <a href="https://clinicaltrials.gov/ct2/show/NCT03815916" target="_blank" class="ke-link">Repair-PD</a>, Apr 2021</td></tr><tr><td>SAGE-718</td><td>NMDA modulator</td><td>Sage Therapeutics</td><td>Ph2 open-label <a href="https://clinicaltrials.gov/show/NCT04476017" target="_blank" class="ke-link">Paradigm</a>, Jun 2021, topline early 2021</td></tr><tr><td>NYX-458</td><td>NMDA modulator</td><td>Aptinyx</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04148391" target="_blank" class="ke-link">Ph2</a>, Jun 2021</td></tr><tr><td>SR-Exenatide (PT320)</td><td>GLP-1 receptor agonist</td><td>Peptron</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04269642" target="_blank" class="ke-link">Ph2</a>, Sep 2021</td></tr><tr><td>Liraglutide (Victoza/Saxenda)</td><td>GLP-1 receptor agonist</td><td>Novo Nordisk</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT02953665" target="_blank" class="ke-link">Ph2</a>, Sep 2021, sponsored by Cedars-Sinai Medical Center</td></tr><tr><td>Adlyxin<br>(lixisenatide)</td><td>GLP-1 receptor agonist</td><td>Sanofi</td><td>Ph2 <a href="https://clinicaltrials.gov/show/NCT03439943" target="_blank" class="ke-link">Lixipark</a>, Sept 2021, sponsored by University Hospital, Toulouse</td></tr><tr><td>ANAVEX 2-73<br>(blarcamesine)</td><td>Muscarinic & sigma-1 receptor agonist</td><td>Anavex Life Sciences</td><td>Improvements in cognitive tests in <a href="https://clinicaltrials.gov/ct2/show/study/NCT03774459" target="_blank" class="ke-link">ph2</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT04575259" target="_blank" class="ke-link">OLE</a> ongoing, Oct 2021</td></tr><tr><td>AXO-Lenti-PD</td><td>Dopamine gene therapy</td><td>Sio Gene Therapies/Oxford Biomedica</td><td>Promising <a href="https://www.eval‎uate.com/vantage/articles/news/snippets/axovant-punished-parkinsons-update" target="_blank" class="ke-link">results from first two cohorts in </a>ph2 <a href="https://clinicaltrials.gov/ct2/show/NCT03720418" target="_blank" class="ke-link">Sunrise-PD</a>; ph2 Explore-PD to start 2021</td></tr><tr><td>NLY01 (pegylated exenatide)</td><td>GLP-1 receptor agonist</td><td>D&D Pharmatech/Neuraly</td><td><a href="https://clinicaltrials.gov/show/NCT04154072" target="_blank" class="ke-link">Ph2</a>, Jul 2022</td></tr><tr><td>CDNF Parkinson’s Project</td><td>Cerebral dopaminergic neurotrophic factor</td><td>Herantis Pharma</td><td>Ph1/2 showed <a href="https://www.eval‎uate.com/vantage/articles/news/snippets/herantis-takes-its-first-steps-parkinsons" target="_blank" class="ke-link">serious adverse events</a> related to the surgery and drug administration process; <a href="https://clinicaltrials.gov/ct2/show/NCT04228653" target="_blank" class="ke-link">ph1/2</a> long-term safety study, Sep 2022</td></tr><tr><td>Bydureon<br>(exenatide)</td><td>GLP-1 receptor agonist</td><td>Astrazeneca</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04305002" target="_blank" class="ke-link">Ph2</a>, Oct 2022, sponsored by Center for Neurology Stockholm and Karonlinska Institutet</td></tr><tr><td>SUN-K706<br>(K0706, SCC-138, vodobatinib)</td><td>BCR-ABL tyrosine kinase inhibitor</td><td>Sun Pharma Advanced Research</td><td>Ph2 <a href="https://clinicaltrials.gov/show/NCT03655236" target="_blank" class="ke-link">Proseek</a>, Mar 2023</td></tr><tr><td>UCB0599</td><td>Alpha-synuclein aggregation inhibitor</td><td>UCB</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04658186" target="_blank" class="ke-link">Ph2</a>, Oct 2023</td></tr><tr><td>PR001</td><td>AAV GBA1 gene therapy</td><td>Lilly/Prevail Therapeutics</td><td>Ph2 <a href="https://clinicaltrials.gov/ct2/show/NCT04127578" target="_blank" class="ke-link">Propel</a>, biomarker data mid 2021, completes Jun 2027</td></tr><tr><td colspan="4" rowspan="1">Sources: Eval‎uatePharma, clinicaltrials.gov & company releases.</td></tr></tbody></table></div><p><a href="https://www.eval‎uate.com/vantage/articles/events/company-events/busy-year-ahead-parkinsons-disease" target="_blank" class="ke-link">https://www.eval‎uate.com/vantage/articles/events/company-events/busy-year-ahead-parkinsons-disease</a></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="A busy year ahead for Parkinson’s disease" data-og-description="As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs." data-og-host="www.eval‎uate.com" data-og-source-url="https://www.eval‎uate.com/vantage/articles/events/company-events/busy-year-ahead-parkinsons-disease" data-og-url="https://www.eval‎uate.com/vantage/articles/events/company-events/busy-year-ahead-parkinsons-disease"><a href="https://www.eval‎uate.com/vantage/articles/events/company-events/busy-year-ahead-parkinsons-disease" target="_blank" data-source-url="https://www.eval‎uate.com/vantage/articles/events/company-events/busy-year-ahead-parkinsons-disease"><div class="og-image" style="background-image:url(null)"></div><div class="og-text"><p class="og-title">A busy year ahead for Parkinson’s disease</p><p class="og-desc">As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.</p><p class="og-host">www.eval‎uate.com</p></div></a></div><p> </p>
<!-- -->
